Evaluating the Impact of Teriflunomide and Dimethyl Fumarate on Quality of Life in Relapsing-remitting Multiple Sclerosis: Insights from Eastern Saudi Arabia
Annals of African Medicine · 2025
DOI: 10.4103/aam.aam_259_24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of African Medicine, 2025. Verfasst von Dhafer Alshayban und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia. Hauptthemen laut MEDLINE: Quality of Life, Multiple Sclerosis, Relapsing-Remitting, Dimethyl Fumarate, Crotonates. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).
Abstract (Originalsprache)
Introduction
Relapsing-remitting multiple sclerosis (RRMS) is a chronic neurological condition prevalent in Saudi Arabia. It causes a spectrum of neurological impairments that result in functional limitations and disability. The physical and psychological burdens of multiple sclerosis (MS) significantly impact patients’ health-related quality of life (HRQoL). However, research evaluating its effects on HRQoL within the Saudi context remains scarce. This study aimed to compare HRQoL among RRMS patients undergoing treatment with teriflunomide or dimethyl fumarate and identify factors influencing treatment outcomes. Methodology: A cross-sectional study involving all MS patients was conducted at King Fahd Hospital of the University from November 2022 to April 2023. Participants were categorized into two groups based on their treatment: those receiving teriflunomide and those on dimethyl fumarate. Data were collected using the EQ-5D-5L questionnaire.
Results
Of the 280 patients invited, 82 RRMS patients met the inclusion criteria, comprising 28 males and 54 females, with most participants over 40. Approximately 43.9% were treated with teriflunomide, whereas 56.1% received dimethyl fumarate. No statistically significant differences were found in the three health indicators assessed between the two treatment groups. Nonetheless, the descriptive analysis indicated that RRMS patients on dimethyl fumarate reported superior health outcomes to those on teriflunomide.
Conclusion
The study revealed that patients with RRMS in the dimethyl fumarate and teriflunomide treatment groups reported low physical and mental HRQoL. While no statistically significant differences were observed between the two groups, those receiving dimethyl fumarate indicated a better QoL than their counterparts on teriflunomide. Future research is necessary to identify specific gaps that could facilitate improvements in HRQoL among RRMS patients. Furthermore, the findings from this study may inform the development and implementation of targeted intervention programs aimed at enhancing HRQoL for RRMS patients within the Saudi population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy Practice, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.
- Department of Neurology, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.
- Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
- Department of Clinical Pharmacy, College of Pharmacy, King Khalid University, Abha, Saudi Arabia.
- Department of Family and Community Medicine, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.
Zitieren
APA
Alshayban, D., Al-Shamrani, F. J., Alamer, K. A., Muazen, M. Y., Alqahtani, K. A., Alsulaiman, L., Islam, M. A., Balkhi, B., Alqahtani, S., & AlHarkan, K. S. (2025). Evaluating the Impact of Teriflunomide and Dimethyl Fumarate on Quality of Life in Relapsing-remitting Multiple Sclerosis: Insights from Eastern Saudi Arabia. Annals of African Medicine. https://doi.org/10.4103/aam.aam_259_24
Vancouver
Alshayban D, Al-Shamrani FJ, Alamer KA, Muazen MY, Alqahtani KA, Alsulaiman L, et al. Evaluating the Impact of Teriflunomide and Dimethyl Fumarate on Quality of Life in Relapsing-remitting Multiple Sclerosis: Insights from Eastern Saudi Arabia. Annals of African Medicine. 2025. doi:10.4103/aam.aam_259_24
BibTeX
@article{Alshayban2025,
author = {Alshayban, Dhafer and Al-Shamrani, Foziah J and Alamer, Khalid A and Muazen, Mohammad Y and Alqahtani, Khalid A and Alsulaiman, Layan and Islam, Md Ashraful and Balkhi, Bander and Alqahtani, Saad and AlHarkan, Khalid S},
title = {Evaluating the Impact of Teriflunomide and Dimethyl Fumarate on Quality of Life in Relapsing-remitting Multiple Sclerosis: Insights from Eastern Saudi Arabia},
journal = {Annals of African Medicine},
year = {2025},
doi = {10.4103/aam.aam_259_24}
}
EUVIMED